Completed PHASE4 INTERVENTIONAL NCT00260247

Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine.

Induction of Drug Metabolism: A Comparative, Pharmacokinetic in Vivo Study of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4.

Sponsor: Danish Research Agency

Conditions Metabolic Clearance Rate

Interventions carbamazepine oxcarbazepine

Updated 5 times since 2017 Last updated: Apr 21, 2015 Started: Apr 30, 2005 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Metabolic Clearance Rate and is currently completed. Danish Research Agency leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Danish Research Agency
Novartis
Odense University Hospital

Data source: Odense University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Odense, Denmark